Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
October 24, 2025 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160
September 15, 2025 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
July 03, 2025 14:15 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
May 08, 2025 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
March 20, 2025 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results
March 11, 2025 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
January 10, 2025 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
January 08, 2025 11:00 ET | Source: Rapafusyn Pharmaceuticals

Rapafusyn Pharmaceuticals to Showcase Its Molecular Glue Drug Discovery Platform at WuXi Global Forum

BALTIMORE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals, a pioneer in non-degrading molecular glue therapeutics, announced today that it will host an executive roundtable at the WuXi...
December 20, 2024 07:12 ET | Source: Research and Markets

Targeted Protein Degradation Industry Forecast to Reach $4.37 Billion by 2034: PROTACs Lead the Charge with Promising Innovations in Oncology

Dublin, Dec. 20, 2024 (GLOBE NEWSWIRE) -- The "Global Targeted Protein Degradation Market by Type, by Application, by End-User, and by Region" report has been added to ResearchAndMarkets.com's...